Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.54 |
| ▸ | MMP3 | P08254 | 6/20 | 0.54 |
| ▸ | MMP9 | P14780 | 6/20 | 0.54 |
| ▸ | MMP13 | P45452 | 6/20 | 0.54 |
| ▸ | MMP1 | P03956 | 5/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 10/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781297 | 0.91 | KEAP1 (0.56) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL3787721 | 0.91 | KEAP1 (0.56) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL3787457 | 0.82 | MMP2 (0.44) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL3777041 | 0.81 | CA12 (0.47) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL4743617 | 0.81 | CYP1A2 (0.53) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL14435543 | 0.79 | CA12 (0.47) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL7229492 | 0.78 | NPSR1 (0.51) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL23089862 | 0.77 | MMP2 (0.48) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL23089863 | 0.77 | MMP2 (0.48) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL5050905 | 0.77 | CA12 (0.49) | MMP2MMP3MMP9MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324305-A1 | PRODUCTION METHOD OF POLYCYCLIC LACTAMS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20090118519-A1 | Production Method of Polycyclic Lactams | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-2014647-A1 | PROCESS FOR PRODUCING POLYCYCLIC LACTAM | Sumitomo Chemical Company, Limited (JP) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118519-A1 | Production Method of Polycyclic Lactams | MRPL21, COASY, ASNS | MMP2 1755/4885MMP3 3452/4885MMP9 2057/4885 |
| US-20100324305-A1 | PRODUCTION METHOD OF POLYCYCLIC LACTAMS | COASY, MRPL21, ASNS | MMP2 1922/4885MMP3 3479/4885MMP9 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.